At age five, Charlotte suffered 300 grand mal seizures a week, and was constantly on the brink of a medical emergency. Through online research, Charlotte’s desperate parents heard of treating Dravet with CBD. It was controversial to pursue medical marijuana for such a young patient, but when they gave Charlotte oil extracted from high-CBD cannabis, her seizures stopped almost completely. In honor of her progress, high-CBD cannabis is sometimes known as Charlotte’s Web.
Epidiolex was developed by the London-based GW Pharmaceuticals, which grows cannabis on tightly controlled farms in the UK. It embarked on the Epidiolex project in 2013, as anecdotes of CBD’s value as an epilepsy drug began emerging from the US.
So far, CBD is the most promising compound from both a marketing and a medical perspective. Many users believe it helps them relax, despite it not being psychoactive, and some believe regular doses help stave off Alzheimer’s and heart disease.
While studies have shown CBD to have anti-inflammatory, anti-pain and anti-psychotic properties, it has seen only minimal testing in human clinical trials, where scientists determine what a drug does, how much patients should take, its side effects and so on.
The first thing to know about CBD is that it is not psychoactive; it doesn’t get people high. The primary psychoactive ingredient in marijuana is tetrahydrocannabinol (THC). But THC is only one of the scores of chemicals – known as cannabinoids – produced by the cannabis plant.
After Charlotte’s story got out, hundreds of families relocated to Colorado where they could procure CBD for their children, though not all experienced such life-changing results. Instead of moving, other families obtained CBD oil through the illegal distribution networks.
Despite the government ruling, CBD is widely available over the counter in dispensaries in states where marijuana is legal.
Add to Mendeley
Δ 9 -tetrahydrocannabinol binds cannabinoid (CB1 and CB2) receptors, which are activated by endogenous compounds (endocannabinoids) and are involved in a wide range of physiopathological processes (e.g. modulation of neurotransmitter release, regulation of pain perception, and of cardiovascular, gastrointestinal and liver functions). The well-known psychotropic effects of Δ 9 -tetrahydrocannabinol, which are mediated by activation of brain CB1 receptors, have greatly limited its clinical use. However, the plant Cannabis contains many cannabinoids with weak or no psychoactivity that, therapeutically, might be more promising than Δ 9 -tetrahydrocannabinol. Here, we provide an overview of the recent pharmacological advances, novel mechanisms of action, and potential therapeutic applications of such non-psychotropic plant-derived cannabinoids. Special emphasis is given to cannabidiol, the possible applications of which have recently emerged in inflammation, diabetes, cancer, affective and neurodegenerative diseases, and to Δ 9 -tetrahydrocannabivarin, a novel CB1 antagonist which exerts potentially useful actions in the treatment of epilepsy and obesity.
Please note that Internet Explorer version 8.x is not supported as of January 1, 2016. Please refer to this support page for more information.
Get Word of the Day daily email!
A daily challenge for crossword fanatics.
Keep scrolling for more
Medical Definition of nonpsychoactive
“Nonpsychoactive.” Merriam-Webster.com Dictionary, Merriam-Webster, https://www.merriam-webster.com/dictionary/nonpsychoactive. Accessed 11 Aug. 2021.
More Definitions for nonpsychoactive
Test your vocabulary with our 10-question quiz!
Cite this Entry